

## **MINORITY SHAREHOLDERS WATCH GROUP**

BADAN PENGAWAS PEMEGANG SAHAM MINORITI BERHAD  
(Incorporated in Malaysia – Registration No.: 200001022382 (524989-M))

New Straits Times, Business Times – Monday, November 8, 2021

### **MSWG AGM/EGM WEEKLY WATCH**

**8 – 12 NOVEMBER 2021**

MSWG had issued AGM/EGM letter to the following PLCs for their shareholders meeting held from 8 – 12 November 2021.

The extraction of the question raised in the letter is highlighted here. For the details of other questions, please login to MSWG website at [www.mswg.org.my](http://www.mswg.org.my)

#### **One of the points of interest to be raised:**

<b>Company</b>	<b>Points/Issues to Be Raised</b>
<b>ACME Holdings Bhd (EGM)</b>	<p>The Group's subsidiary, Supportive Technology Sdn Bhd ("STSB") has an outstanding trade receivable of RM 1,323,727. STSB has collected RM212,914 of this outstanding amount. (Page 6 of the Circular).</p> <p>(a) Please name the trade debtor(s) who have yet to settle the outstanding debt?</p> <p>(b) Why was STSB unable to collect the remaining outstanding trade receivables?</p> <p>(c) What are the measures taken to recover the outstanding trade receivables?</p> <p>(d) What is the probability that STSB will be able to recover the outstanding trade receivables? What is the expected amount to be collected?</p>
<b>Key Asic Bhd (AGM)</b>	<p>The Group's allowance for impairment losses on trade receivables amounting to RM18.96 million represents 96% of the Group's trade receivables of RM19.74 million in FY2021 (Note 9, page 94 of AR 2021).</p> <p>(a) What are the profiles of the customers with long outstanding trade receivables? Please include details such as country, amount due, overdue period etc.</p> <p>(b) What actions have been taken to recover the said amount?</p> <p>(c) What percentage of these impairments are expected to be non-recoverable?</p> <p>(d) To-date, how much of these impaired trade receivables have been recovered?</p>
<b>Ucrest Bhd (fka Palette Multimedia Bhd) (AGM)</b>	<p>On 6 September 2021, Ucrest Technology Ltd, a wholly owned subsidiary of the Company, entered into a Master Service Agreement with Limited Liability Company "Human Vaccine", a wholly owned subsidiary of Russia Direct Investment Fund ("RDIF") for production of Sputnik V vaccines, following the MOU signed between the Company and RDIF (Note 32, page 141 of AR2021).</p> <p>When is the expected commencement of delivery of the Sputnik V vaccines? How and to what extent will it contribute to the Group's revenue for financial year ending 2022 and going forward?</p>